Heise C - Search Results

1

Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.

Heise C, Ganly I, Kim YT, Sampson-Johannes A, Brown R, Kirn D. Heise C, et al. Gene Ther. 2000 Nov;7(22):1925-9. doi: 10.1038/sj.gt.3301319. Gene Ther. 2000. PMID: 11127580

2

Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy.

Heise CC, Williams AM, Xue S, Propst M, Kirn DH. Heise CC, et al. Cancer Res. 1999 Jun 1;59(11):2623-8. Cancer Res. 1999. PMID: 10363984

3

Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects.

Heise CC, Williams A, Olesch J, Kirn DH. Heise CC, et al. Cancer Gene Ther. 1999 Nov-Dec;6(6):499-504. doi: 10.1038/sj.cgt.7700071. Cancer Gene Ther. 1999. PMID: 10608346

4

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.

Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F. Bischoff JR, et al. Among authors: heise c. Science. 1996 Oct 18;274(5286):373-6. doi: 10.1126/science.274.5286.373. Science. 1996. PMID: 8832876

5

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.

Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. Heise C, et al. Nat Med. 1997 Jun;3(6):639-45. doi: 10.1038/nm0697-639. Nat Med. 1997. PMID: 9176490

6

Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration.

Heise C, Lemmon M, Kirn D. Heise C, et al. Clin Cancer Res. 2000 Dec;6(12):4908-14. Clin Cancer Res. 2000. PMID: 11156251

7

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.

Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D. Mulvihill S, et al. Among authors: heise c. Gene Ther. 2001 Feb;8(4):308-15. doi: 10.1038/sj.gt.3301398. Gene Ther. 2001. PMID: 11313805 Clinical Trial.

8

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy.

Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D. Heise C, et al. Nat Med. 2000 Oct;6(10):1134-9. doi: 10.1038/80474. Nat Med. 2000. PMID: 11017145

9

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.

Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH, Heise CC, Kirn DH. Rogulski KR, et al. Among authors: heise cc. Cancer Res. 2000 Mar 1;60(5):1193-6. Cancer Res. 2000. PMID: 10728673

10

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, Robertson AG, Park O, Gulley ML, Heise C, Von Hoff DD, Kaye SB. Ganly I, et al. Among authors: heise c. Clin Cancer Res. 2000 Mar;6(3):798-806. Clin Cancer Res. 2000. PMID: 10741699 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

335 results

Search Page

Filters